J9301 Obinutuzumab - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Obinutuzumab

Brand Name:

Gazyva

Strength:

10 mg

HCPCS:

J9301

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

CD20

Oral (Y/N):

No

FDA Approval Year:

2013

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2015

CMS Discontinuation Date:

Status:

In Use